AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16998653 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis (LIF)
Number of subjects: 63
Study 16998653 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 63
Study 15259905 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily saquinavir/ritonavir 1600/100 mg
Number of subjects: 18
Study 15259905 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily saquinavir/ritonavir 2000/100 mg
Number of subjects: 18
Study 15259905 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily saquinavir/ritonavir 1000/100 mg
Number of subjects: 18
Study 10380965 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related fMRI analysis during number comparison tasks
Number of subjects: 0
Study 8696719 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin‐navelbine‐cisplatin (MNP)
Number of subjects: 209
Study 8696719 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin‐vindesine‐cisplatin (MVP)
Number of subjects: 209
Study 2060551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD) 0.8, 1.6, and 3.2 mg/day
Number of subjects: 12
Study 2060551 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (PRED) 5, 10, and 20 mg/day
Number of subjects: 12
Study 2060551 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of BUD and PRED
Number of subjects: 12
Study 6841392 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy within 48 hours of myelography (Group 1)
Number of subjects: 0
Study 6841392 — intervention group
Group type: COMPARATOR
Intervention: Discectomy at least seven days after myelography (Group 2)
Number of subjects: 0
Study 31923301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic device
Number of subjects: 16
Study 31923301 — intervention group
Group type: COMPARATOR
Intervention: Conventional drills
Number of subjects: 16
Study 30943934 — intervention group
Group type: EXPERIMENTAL
Intervention: Great Live and Move Challenge (GLMC) intervention delivered over 3.5 months per year for two years.
Number of subjects: 4000
Study 30943934 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 4000
Study 27544575 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium clips (group A)
Number of subjects: 220
Study 27544575 — intervention group
Group type: COMPARATOR
Intervention: Bipolar coagulation (group B)
Number of subjects: 220
Study 25467598 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Feeding (BF)
Number of subjects: 250
Study 25467598 — intervention group
Group type: COMPARATOR
Intervention: Music Therapy (MT)
Number of subjects: 250
Study 25467598 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Breast Feeding and Music Therapy (BF+MT)
Number of subjects: 250
Study 25467598 — intervention group
Group type: COMPARATOR
Intervention: No Intervention (Control)
Number of subjects: 250
Study 23837690 — intervention group
Group type: EXPERIMENTAL
Intervention: Go-rei-San (GRS) 7.5 g orally the day before surgery
Number of subjects: 100
Study 23837690 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 100
Study 21845249 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized Ridge Expanders (MRE)
Number of subjects: 8
Study 21845249 — intervention group
Group type: COMPARATOR
Intervention: Lateral Ridge Augmentation (LRA)
Number of subjects: 8
Study 18059031 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha tocopherol (400 IU/day) and beta carotene (30 mg/day) supplements
Number of subjects: 540
Study 18059031 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 540
Study 16814130 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Empowerment Model (PEM)
Number of subjects: 60
Study 16814130 — intervention group
Group type: COMPARATOR
Intervention: Compliance-based Model (CEM)
Number of subjects: 60
Study 16814130 — intervention group
Group type: COMPARATOR
Intervention: Net reduction between PEM and CEM
Number of subjects: 60
Study 15232810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium chloride (MgCl2), 50 mmol/24 hours, administered for 36 hours after induction of anesthesia
Number of subjects: 147
Study 15232810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 11086757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape
Number of subjects: 8
Study 11086757 — intervention group
Group type: EXPERIMENTAL
Intervention: Braces
Number of subjects: 8
Study 11086757 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Number of subjects: 8
Study 11086757 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoes
Number of subjects: 8
Study 8882841 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing socially stressful situations (Caucasian perpetrator)
Number of subjects: 92
Study 8882841 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing socially stressful situations (Black perpetrator)
Number of subjects: 92
Study 1370509 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate exposure (dihydrocodeine, hydrocodone, codeine, morphine)
Number of subjects: 39
Study 1370509 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate exposure
Number of subjects: 39
Study 1370509 — intervention group
Group type: COMPARATOR
Intervention: Atopic status (positive cutaneous test results to two or more of nine common aeroallergens)
Number of subjects: 39
Study 6372855 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir for 7 days
Number of subjects: 31
Study 6372855 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 31
Study 3015401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (lomustine, cyclophosphamide, vincristine, cisplatin, and doxorubicin monthly)
Number of subjects: 47
Study 3015401 — intervention group
Group type: COMPARATOR
Intervention: Group B (five-drug regimen on Months 1, 3, and 5; 5-FU by constant infusion, methotrexate, and mitomycin on Months 2, 4, and 6)
Number of subjects: 47
Study 29125718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 24
Study 29125718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 24
Study 29125718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted condition
Number of subjects: 24
Study 29125718 — intervention group
Group type: COMPARATOR
Intervention: Overall (all meal conditions)
Number of subjects: 24
Study 28317362 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticle-labeled group (experimental group)
Number of subjects: 96
Study 28317362 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 24315294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% prednisolone sodium phosphate
Number of subjects: 500
Study 24315294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 22129231 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic BioSand Water Filter (BSF)
Number of subjects: 1147
Study 22129231 — intervention group
Group type: COMPARATOR
Intervention: Control villages
Number of subjects: 1147
Study 20451538 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT (dairy fats)
Number of subjects: 18
Study 20451538 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (coconut oil)
Number of subjects: 18
Study 20451538 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT (beef tallow)
Number of subjects: 18
Study 17947341 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg q.d.)
Number of subjects: 179
Study 17947341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 15916709 — intervention group
Group type: EXPERIMENTAL
Intervention: Irvingia gabonensis (IG) 1.05 g three times a day for one month
Number of subjects: 40
Study 15916709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40
Study 12842747 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (GBP)
Number of subjects: 36
Study 12842747 — intervention group
Group type: COMPARATOR
Intervention: Open gastric bypass (GBP)
Number of subjects: 36
Study 10381282 — intervention group
Group type: EXPERIMENTAL
Intervention: Longeval subjects (85-102 years)
Number of subjects: 279
Study 10381282 — intervention group
Group type: EXPERIMENTAL
Intervention: Seniors (65-75 years)
Number of subjects: 279
Study 10381282 — intervention group
Group type: COMPARATOR
Intervention: MTHFR gene mutation
Number of subjects: 279
Study 8621995 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown factors associated with carrying a first live birth
Number of subjects: 14948
Study 8621995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 14948
Study 8621995 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age greater than 30 years
Number of subjects: 14948
Study 8621995 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive urine culture
Number of subjects: 14948
Study 8621995 — intervention group
Group type: EXPERIMENTAL
Intervention: Women over 150 pounds at the onset of pregnancy
Number of subjects: 14948
Study 8621995 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal urine protein > or = 2+
Number of subjects: 14948
Study 8621995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking during the first trimester
Number of subjects: 14948
Study 1812901 — intervention group
Group type: EXPERIMENTAL
Intervention: Plax pre-brushing rinse followed by brushing with ADA-approved toothbrush and fluoride toothpaste
Number of subjects: 19
Study 1812901 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-brushing rinse followed by brushing with ADA-approved toothbrush and fluoride toothpaste
Number of subjects: 19
Study 6682617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (225 mg/day)
Number of subjects: 49
Study 6682617 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (160 mg/day)
Number of subjects: 49
Study 6682617 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Hydralazine and Isosorbide dinitrate (H + I)
Number of subjects: 49
Study 6682617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 49
Study 6682617 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (I)
Number of subjects: 49
Study 31743507 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise intervention
Number of subjects: 30
Study 31743507 — intervention group
Group type: COMPARATOR
Intervention: Time-matched contact control condition
Number of subjects: 30
Study 28885231 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortwave diathermy (SWD) in NP(+) group
Number of subjects: 57
Study 28885231 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortwave diathermy (SWD) in NP(-) group
Number of subjects: 57
Study 28885231 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment in NP(+) group
Number of subjects: 57
Study 28885231 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment in NP(-) group
Number of subjects: 57
Study 26486999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided breast-conserving surgery (USS)
Number of subjects: 134
Study 26486999 — intervention group
Group type: COMPARATOR
Intervention: Standard palpation-guided surgery (PGS)
Number of subjects: 134
Study 25265449 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 667
Study 25265449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 22722664 — intervention group
Group type: EXPERIMENTAL
Intervention: DAWBA disclosed (n = 144)
Number of subjects: 270
Study 22722664 — intervention group
Group type: COMPARATOR
Intervention: DAWBA non-disclosed (n = 126)
Number of subjects: 270
Study 20406686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 19
Study 20406686 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 19
Study 20406686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus and Cyclosporine
Number of subjects: 19
Study 16928779 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise education intervention program (12 weeks)
Number of subjects: 116
Study 16928779 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 116
Study 15672849 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-limited NPPV
Number of subjects: 15
Study 15672849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-limited NPPV
Number of subjects: 15
Study 11585015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy targeting diastolic dysfunction
Number of subjects: 0
Study 9143253 — intervention group
Group type: EXPERIMENTAL
Intervention: Live oral polio virus vaccine
Number of subjects: 14
Study 9143253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7496197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine therapy at the beginning of the nervous stage
Number of subjects: 0
Study 7496197 — intervention group
Group type: COMPARATOR
Intervention: Arsobal therapy (2, 16 mg/kg/d for 10 consecutive days)
Number of subjects: 0
Study 7496197 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO therapy
Number of subjects: 0
Study 7496197 — intervention group
Group type: EXPERIMENTAL
Intervention: MLD 73811 and IMOL 881
Number of subjects: 0
Study 2897207 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-mimetic tocolytic administration
Number of subjects: 890
Study 31158266 — intervention group
Group type: EXPERIMENTAL
Intervention: Water filters and portable biomass-burning natural draft rocket-style cookstoves
Number of subjects: 1582
Study 28701336 — intervention group
Group type: EXPERIMENTAL
Intervention: Reframe-IT plus treatment as usual (TAU)
Number of subjects: 50
Study 28701336 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 50
Study 28701336 — intervention group
Group type: EXPERIMENTAL
Intervention: Reframe-IT plus TAU
Number of subjects: 50
Study 26565938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate flow (Qd) of 600ml/min
Number of subjects: 37
Study 26565938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate flow (Qd) of 700ml/min
Number of subjects: 37
Study 26565938 — intervention group
Group type: COMPARATOR
Intervention: Dialysate flow (Qd) of 500ml/min
Number of subjects: 37
Study 23835112 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine and Olmesartan (A/O)
Number of subjects: 66
Study 23835112 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide and Losartan (L/H)
Number of subjects: 66
Study 21226640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 21226640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19822078 — intervention group
Group type: EXPERIMENTAL
Intervention: rhMCP-1 (0.02-2.0 microg/kg)
Number of subjects: 36
Study 19822078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17343938 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy at 2 Gy/fraction/day, 5 days/week to 70 Gy/7 weeks
Number of subjects: 154
Study 17343938 — intervention group
Group type: EXPERIMENTAL
Intervention: Split course bifractionated radiotherapy at 1.6 Gy/fraction, twice daily, 5 days/week to 70.4 Gy/6 weeks
Number of subjects: 154
Study 14998241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 39
Study 14998241 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 39
Study 11913269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin tablet containing seven active ingredients
Number of subjects: 63
Study 11913269 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 63
Study 9436668 — intervention group
Group type: EXPERIMENTAL
Intervention: Normegon
Number of subjects: 36
Study 9436668 — intervention group
Group type: EXPERIMENTAL
Intervention: Follegon
Number of subjects: 36
Study 9436668 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrodin HP
Number of subjects: 36
Study 9436668 — intervention group
Group type: COMPARATOR
Intervention: Normegon, Follegon, Metrodin HP
Number of subjects: 36
Study 7894117 — intervention group
Group type: EXPERIMENTAL
Intervention: Early radiotherapy (40 Gy in 15 fractions)
Number of subjects: 308
Study 7894117 — intervention group
Group type: COMPARATOR
Intervention: Late radiotherapy (40 Gy in 15 fractions)
Number of subjects: 308
Study 7894117 — intervention group
Group type: EXPERIMENTAL
Intervention: Early radiotherapy
Number of subjects: 308
Study 2465949 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 (5 ng/kg/min)
Number of subjects: 0
Study 2465949 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (25 ng/kg/min)
Number of subjects: 0
Study 2465949 — intervention group
Group type: EXPERIMENTAL
Intervention: CG 4203 (25 ng/kg/min)
Number of subjects: 0
Study 2465949 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (1 and 2 ng/kg/min)
Number of subjects: 0
Study 30507958 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VR application
Number of subjects: 50
Study 30507958 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive VR application
Number of subjects: 50
Study 30507958 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 50
Study 27716865 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity physical activity (LIPA) - 2.5 hours of prolonged sitting with 2-minute bouts of walking every 20 minutes
Number of subjects: 14
Study 27716865 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - 2.5 hours of prolonged sitting
Number of subjects: 14
Study 27716865 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LIPA and CON
Number of subjects: 14
Study 26431252 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth (group 1)
Number of subjects: 180
Study 26431252 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination at 34 weeks post conception age (group 2)
Number of subjects: 180
Study 23629985 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial arch orthosis (n=55)
Number of subjects: 81
Study 23629985 — intervention group
Group type: COMPARATOR
Intervention: Analgesics (control group, n=26)
Number of subjects: 81
Study 21586313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace conditioning with contingency awareness
Number of subjects: 0
Study 21586313 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay conditioning with contingency awareness
Number of subjects: 0
Study 21586313 — intervention group
Group type: COMPARATOR
Intervention: Trace conditioning without contingency awareness
Number of subjects: 0
Study 21586313 — intervention group
Group type: COMPARATOR
Intervention: Delay conditioning without contingency awareness
Number of subjects: 0
Study 19322104 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid supplementation
Number of subjects: 1444
Study 19322104 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 1444
Study 19322104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1444
Study 16860062 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI) with magnifying endoscopy
Number of subjects: 63
Study 15016635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced preconditioning (FWOP)
Number of subjects: 20
Study 15016635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (SWOP)
Number of subjects: 20
Study 15016635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologically induced preconditioning (PI-SWOP) with 10 mg nitroglycerin
Number of subjects: 20
Study 15016635 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study 11214746 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-coated stents
Number of subjects: 30
Study 11214746 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents
Number of subjects: 30
Study 11214746 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stents
Number of subjects: 30
Study 8708426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle pressure recommendation amendment from < or = 50 mmHg to >50 mmHg
Number of subjects: 140
Study 8708426 — intervention group
Group type: EXPERIMENTAL
Intervention: Big toe pressure recommendation amendment from < or = 30 mmHg to >30 mmHg
Number of subjects: 140
Study 8708426 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of Doppler index and tcPO2 as additional parameters
Number of subjects: 140
Study 2650695 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplement (10 g of fish oil containing 3 g n-3 fatty acids, 1.8 g eicosapentaenoic acid)
Number of subjects: 0
Study 2650695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isoenergetic supplement containing olive oil)
Number of subjects: 0
Study 334110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin sodium (1 gm IV at the beginning of operation and 1 gm one hour later)
Number of subjects: 0
Study 334110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin sodium (2 gm IV)
Number of subjects: 0
Study 334110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31567810 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients requesting appointments via telephone
Number of subjects: 71
Study 31567810 — intervention group
Group type: COMPARATOR
Intervention: English-speaking patients requesting appointments via telephone
Number of subjects: 71
Study 31567810 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients instructed to bring a friend or family member for translation
Number of subjects: 71
Study 31567810 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients told that the provider spoke sufficient Spanish
Number of subjects: 71
Study 31567810 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients told that an interpreter would be available
Number of subjects: 71
Study 31567810 — intervention group
Group type: COMPARATOR
Intervention: Comparison of access to appointments between Spanish-speaking and English-speaking patients
Number of subjects: 71
Study 29384903 — intervention group
Group type: EXPERIMENTAL
Intervention: tedizolid phosphate 200 mg once daily for 6 days
Number of subjects: 813